Search for European Projects

31 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Translating neuroimaging findings from research into clinical practice (PSYSCAN)

Start date: Feb 1, 2014, End date: Jan 31, 2020,

Abstract 9Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standard ...
Read Project

 24

 FINISHED 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Start date: Jan 1, 2015, End date: Dec 31, 2019,

...ty for AD prevention trials with limited clinical background is both a risky and cost-inefficient strategy. Creating a disease register of people consented to enter secondary prevention trials delivers a degree of readiness that ensures better knowledge of a participants suitability and a more rapid throughput of screening for the trials. The EPAD Consortium has the necessary reach and influence f ...
Read Project

 40

 FINISHED 

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)

Start date: Jan 1, 2015, End date: Dec 31, 2019,

Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Read Project

 34

 FINISHED 

Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)

Start date: Jul 1, 2014, End date: Jun 30, 2019,

...armaceutical investigations; (5) identification of biomarkers and health technology solutions to be implemented into clinical practice. Thus, the project is expected to pursue all the research deliverables described in nine work-packages.The SPRINTT project proposes a novel operationalisation of physical frailty recognising sarcopenia as its central biological substrate. This approach is based on ...
Read Project

 27

 FINISHED 

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)

Start date: Feb 1, 2014, End date: Jan 31, 2019,

...), Sjögren’s syndrome (Sjs), rheumatoid arthritis (RA), primary antiphospholipid syndrome (PAPS) and mixed connective tissue disease (MCTD), jointly as systemic autoimmune diseases (SADs). We believe that there will be overlapping clusters of individuals across diseases that will share molecular features. To determine these clusters we will, study 2000 cases of SADs, and 600 healthy controls to id ...
Read Project

 30

 FINISHED 

DIabetes REsearCh on patient sTratification (DIRECT)

Start date: Feb 1, 2012, End date: Jan 31, 2019,

The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Read Project

 27

 FINISHED 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

...lligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for full environmental risk assessment and/or environmental (bio) monitoring. The aim will be delivered through a number of specific objectives: 1) to review existing approaches for prioritisation and mode of action based intelligent testing of APIs and develop improved frameworks; 2) to establ ...
Read Project

 29

 FINISHED 

REgeneration of inner ear hair cells with GAmma-secretase INhibitors to regain hearing in patients with sensorineural hearing loss (REGAIN)

Start date: May 1, 2015, End date: Oct 31, 2018,

Hearing loss is a chronic non-communicable disease disabling over 328 million adults, and 32 million children worldwide. Sensorineural hearing loss due to loss of auditory hair cells was long thought to be irreversible. However, recent animal studies have demonstrated that pharmacological inhibition of cell signalling via Notch receptors using gamma-secretase inhibitors (GSIs) can regenerate hair ...
Read Project

 7

 FINISHED 

Diagnostic and Drug Discovery Initiative for Alzheimer’s Disease (D3i4AD)

Start date: Oct 1, 2014, End date: Sep 30, 2018,

...ich has no cure at the moment. The overall aim of the work described in this proposal is to create a long-term strategic partnership between Sheffield University (UK), Lisbon University (Portugal), Eli Lilly (UK) and Biofordrug (Italy) in order to develop chemical biology tools for better understanding the role of PrPC in AD and harnessing this understanding to develop novel chemical entities for ...
Read Project

 5

 FINISHED 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Start date: Sep 1, 2011, End date: Dec 31, 2017,

... consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision-making in Phase ...
Read Project

 26

 FINISHED 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

...sary overheads and a substantial risk to the legacy of datasets. The end result is a less than full realization of the potential of IMI to diminish bottlenecks in drug and diagnostic development. ’Delivering eTRIKS’ will address this gap by providing a sustainable, open IMI translational research informatics/KM platform – eTRIKS, and delivering associated support, expertise and services. Developme ...
Read Project

 17

 FINISHED 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Read Project

 38

 FINISHED 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Start date: Apr 1, 2012, End date: Mar 31, 2017,

...of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories which provide a collection of biologically heterogeneous patients. Further, even if novel treatments are developed there is no EU platform to clinic ...
Read Project

 29

 FINISHED 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

...cademy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocates and advisors, e.g. in pharmaceutical deve ...
Read Project

 33

 FINISHED 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Read Project

 29

 FINISHED 

European Bank for induced pluripotent Stem Cells (EBISC)

Start date: Jan 1, 2014, End date: Dec 31, 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Read Project

 30

 FINISHED 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Start date: Jan 1, 2011, End date: Dec 31, 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Read Project

 22

 FINISHED 

Incorporating real-life clinical data into drug development (GETREAL)

Start date: Oct 1, 2013, End date: Dec 31, 2016,

...t uncertainty relating to the reimbursement, and thus market implementation of new medication once approved by regulatory authorities, is negatively affecting the value of the drug development pipeline. The costly clinical developments to get to market approval, no longer seem to be a guarantee for market entry. This new risk presents a serious additional hurdle for drug developers that already fa ...
Read Project

 32

 FINISHED 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Start date: Jan 1, 2010, End date: Nov 30, 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project

 34

 FINISHED 

Drug Disease Model Resources (DDMORE)

Start date: Mar 1, 2011, End date: Aug 31, 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project

 28

 FINISHED 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Start date: Sep 1, 2009, End date: Jun 30, 2016,

...lona, the Erasmus University Medical Center, the University of Utrecht, the University of Hert[ordshire, the University of Verona, the Karolinska Institute and the European Medicines Agency. It will deliver programmes in harmacovigilance and Pharmacoepidemiology for continuing education diploma, Master’s degree as well as PhD and a short course orientated towards risk communication. Targetedaudien ...
Read Project

 24

 FINISHED 

The Open Pharmacological Concepts Triple Store (OPEN PHACTS)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Read Project

 32

 FINISHED 

Electronic Health Record systems for Clinical Research (EHR4CR)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Read Project

 37

 FINISHED 

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)

Start date: Jan 1, 2010, End date: Dec 31, 2015,

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Read Project

 38

 FINISHED 

Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia (CRESTAR)

Start date: Nov 1, 2011, End date: Oct 31, 2015,

Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Europeans), a considerable economic and social burden. First-line treatments include atypical (e.g. olanzapine) and typical (e.g. haloperidol) antipsychotics. The original atypical, clozapine, is a final option, and although it is the only antipsychotic shown to b ...
Read Project

 11

 FINISHED 

SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT)

Start date: Nov 1, 2009, End date: Oct 31, 2015,

Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as we ...
Read Project

 27

 FINISHED 

Understanding chronic pain and improving its treatment (EUROPAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2015,

...and mutually supportive programs of experimental research, underpinned and supported by a coordinated training and bioinformatics facility. These programs will form a series of workpackages each delivered through collaboration of network laboratories to bring together multiple techniques and considerable expertise to each area. In addition, there will be considerable synergies between the programs ...
Read Project

 29

 FINISHED 

Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)

Start date: Feb 1, 2010, End date: Sep 30, 2015,

...onsortium of leading European experts from universities and SMEs in the fields of beta-cell diabetes research,gene transfer technology, metabolom ics, biomedical imaging, bioinformatics and systemsmodeling. We propose a work plan composed of 5 scientific work packages structured to provide high levels of interaction within the network and with EFPIA partners.A management and administration work pa ...
Read Project

 23

 FINISHED 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Start date: Jun 15, 2009, End date: Jun 14, 2015,

...IcatIon of drug-Induced organ injury (DILl, DIKI and DIVI) safety BM5. SAFE-T objectives will be achieved through innovative biomarkerapproaches employing leading BM technologies.The consortium will deliver a validated generic qualification process for translational safety BMs that will be released for discussion to gain its acceptance as a reference guideline by stakeholders including EFPIA and h ...
Read Project

 26

 FINISHED 

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)

Start date: Sep 1, 2009, End date: Apr 30, 2015,

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Read Project

 36

 FINISHED 

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)

Start date: Sep 1, 2009, End date: Feb 28, 2015,

...e of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical trials on DSM categories which provide a collection of biologically heterogeneous patients. Our broad working hypothesis is that a focus on cross-species endophenotypes, testing in hea ...
Read Project

 20